secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001628280-25-010422
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive starts Anaphylm NDA filing; Q4 net loss $17.1M; 2025 revenue guidance $47-56M
--------------------------------------------------------------------------------

- Q4 2024 total revenues $11.9M, down 10% YoY; full-year revenues $57.6M, up 14%.
- Q4 net loss $17.1M ($0.19/sh) vs $8.1M loss ($0.12/sh) YoY; FY net loss $44.1M ($0.51/sh) vs $7.9M ($0.13/sh).
- Anaphylm NDA submission started, FDA acceptance expected Q2 2025; launch targeted Q1 2026 if approved.
- AQST-108 Phase 2a in alopecia areata to begin Q2 2025; Libervant court ruling appealed, product remains on market.
- Pro-forma cash ~$93M including $21.4M ATM proceeds in Feb 2025; 2025 revenue guidance $47-56M, Non-GAAP EBITDA loss $46-53M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/0001628280-25-010422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-20250305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-010422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer